Expertise in
60
conditions

Dr. Henry T. Tsai

Hematology
Eisenhower Health
39000 Bob Hope Dr, 
Rancho Mirage, CA 
Offers Telehealth
Expertise in
60
conditions
Eisenhower Health
39000 Bob Hope Dr, 
Rancho Mirage, CA 

Overview

Henry Tsai is a Hematologist practicing medicine in Rancho Mirage, California.

Dr. Tsai is highly rated in 60 conditions, according to our data. His clinical expertise encompasses Agranulocytosis, Febrile Neutropenia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Advanced Bronchoscopy.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 8 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in CA

Hospital Affiliations

Desert Regional Medical Center
Loma Linda University Medical Center
Eisenhower Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Eisenhower Health
39000 Bob Hope Dr, Rancho Mirage, CA 92270

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: May 20, 2026
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2026
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Phase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients With Stage II/III,Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation With Lymph Node Irradiation
Phase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients With Stage II/III,Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation With Lymph Node Irradiation
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Radiation
Study Phase: Phase 2
View 7 Less Clinical Trials

3 Total Publications

Early-Onset Colorectal and Gastric Adenocarcinomas in a Patient With a Heterozygous BLM p.E1317K Variant of Uncertain Significance.
Early-Onset Colorectal and Gastric Adenocarcinomas in a Patient With a Heterozygous BLM p.E1317K Variant of Uncertain Significance.
Journal: Cureus
Published: June 24, 2026
Similar Doctors
Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

Loma Linda Univ Anesthesiology Medical Group Inc

11234 Anderson St, 
Loma Linda, CA 
 (53.1 miles away)
909-558-4910
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mojtaba Akhtari is a Hematologist practicing medicine in Loma Linda, California. Dr. Akhtari is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

Eisenhower Lucy Curci Cancer Center

39000 Bob Hope Dr, 
Rancho Mirage, CA 
 (0.1 miles away)
760-346-7655
Languages Spoken:
English
See accepted insurances

Iliana Popescu is a Hematologist practicing medicine in Rancho Mirage, California. Dr. Popescu is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Myelodysplastic Syndrome (MDS), HER2 Negative Breast Cancer, BRCA Positive Breast Cancer, and ALK-Positive Non-Small Cell Lung Cancer.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Hematology/Oncology Consultants

301 N San Jacinto St, 
Hemet, CA 
 (31.8 miles away)
951-766-6460
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Evelyn Mendoza is a Hematologist practicing medicine in Hemet, California. Dr. Mendoza is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Vitamin B12 Deficiency, Agranulocytosis, Myelodysplastic Syndrome (MDS), Squamous Cell Carcinoma of the Anal Canal (SCAC), and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Henry T. Tsai

How do I make an appointment with Dr. Henry T. Tsai?

You can book an appointment with Dr. Henry T. Tsai by calling their office at 760-346-7655. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Henry T. Tsai a top-rated expert for Agranulocytosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Henry T. Tsai is classified as an Distinguished expert for Agranulocytosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Henry T. Tsai specialize in?

While Dr. Henry T. Tsai is a Hematology, they have specific expertise in Agranulocytosis, Febrile Neutropenia, and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Henry T. Tsai participate in research or clinical trials?

Yes. Dr. Henry T. Tsai has published 3 articles and abstracts on conditions like Agranulocytosis. You can view a list of Dr. Henry T. Tsai's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Henry T. Tsai accept my insurance?

Dr. Henry T. Tsai accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 760-346-7655 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tsai's expertise for a condition
ConditionClose
    View All 22 Distinguished Conditions
    View All 38 Advanced Conditions
    View All 74 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile